Quick Answer
SUTRO BIOPHARMA, INC. reported Long Term Debt of $0.00 for the year ending 2023.
- SUTRO BIOPHARMA, INC. showed a decrease of -100.0% in Long Term Debt from 2022 to 2023.
- This data is from SUTRO BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 25, 2024.
- XBRL data for this metric is available from 2018 to 2023 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $11.50 million | Q1 2019: $8.50 million | Q2 2019: $7.00 million | Q3 2019: $5.50 million | Q1 2020: $24.16 million | Q2 2020: $24.28 million | Q3 2020: $24.41 million | Q1 2021: $24.68 million | Q2 2021: $21.69 million | Q3 2021: $18.71 million | Q1 2022: $12.76 million | Q2 2022: $9.78 million | Q3 2022: $6.78 million.
- Over the full 6 years of available data (2018 to 2023), SUTRO BIOPHARMA, INC.'s Long Term Debt has declined by 100.0%.
- Historical annual values: Fiscal year 2023: $0.00 | Fiscal year 2022: $3.77 million | Fiscal year 2021: $15.74 million | Fiscal year 2020: $24.55 million | Fiscal year 2019: $8.88 million | Fiscal year 2018: $10.00 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: